Management of surgical hemostasis: systemic agents.
Despite improvements in surgical techniques, the risk for perioperative bleeding remains significant. Transfusion of allogeneic red blood cells, platelets, and hemostatic factors remains the mainstay of current therapy strategy for management of perioperative bleeding. Transfusions significantly contribute to perioperative adverse events. Pharmacologic strategies to prevent or decrease perioperative bleeding are also important therapeutic approaches to reduce the need for allogeneic transfusions. This article discusses systemic pharmacologic prohemostatic agents (aprotinin, lysine analogues, protamine, desmopressin, and recombinant factor VIIa).
Levy
Jerrold H
JH
Department of Anesthesiology, Emory University Hospital, 1364 Clifton Road, NE, Atlanta, GA 30322, USA. Jerrold.Levy@emoryhealthcare.org
Tanaka
Kenichi A
KA
D000925:Anticoagulants / Q000009:adverse effects; D001777:Blood Coagulation / Q000187:drug effects*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D006488:Hemostasis, Surgical / Q000009:adverse effects / Q000379:methods*; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019106:Postoperative Hemorrhage / Q000097:blood / Q000517:prevention & control*; D018570:Risk Assessment; D012307:Risk Factors; D065227:Transfusion Reaction; D016896:Treatment Outcome
D000925:Anticoagulants; D006490:Hemostatics